Joshua Hunsberger
Joshua Hunsberger has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Anthony Atala
Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
4 shared publications- Anthony Atala
Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, North Carolina, USA
4 shared publications - Carl Simon Shelley
Leukemia Therapeutics, LLC, Hull, USA
2 shared publications Claudia Zylberberg
Akron Biotech, Boca Raton, Florida, USA
2 shared publicationsJulie Allickson
Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, USA
2 shared publicationsShannon Eaker
Cytiva , Marlborough, Massachusetts, USA
2 shared publications
Latest Publications
- 19 July 2021
- Published by Springer Nature in Bio-Design and Manufacturing
- Vol. 5 (1) , 43-63
Bioreactor design and validation for manufacturing strategies in tissue engineering
The fields of regenerative medicine and tissue engineering offer new therapeutic options to restore, maintain or improve tissue function following disease or injury. To maximize the biological function of a tissue-engineered clinical product, specific conditions must be maintained within a bioreactor to allow the maturation of the product in preparation for implantation. Specifically, the bioreactor should be designed to mimic the mechanical, electrochemical and biochemical environment that the product will be exposed to in vivo. Real-time monitoring of the functional capacity of tissue-engineered products during manufacturing is a critical component of the quality management process. The present review provides a brief overview of bioreactor engineering considerations. In addition, strategies for bioreactor automation, in-line product monitoring and quality assurance are discussed.
- 19 July 2021
- Published by Springer Nature in Bio-Design and Manufacturing
- Vol. 5 (1) , 43-63
Bioreactor design and validation for manufacturing strategies in tissue engineering
The fields of regenerative medicine and tissue engineering offer new therapeutic options to restore, maintain or improve tissue function following disease or injury. To maximize the biological function of a tissue-engineered clinical product, specific conditions must be maintained within a bioreactor to allow the maturation of the product in preparation for implantation. Specifically, the bioreactor should be designed to mimic the mechanical, electrochemical and biochemical environment that the product will be exposed to in vivo. Real-time monitoring of the functional capacity of tissue-engineered products during manufacturing is a critical component of the quality management process. The present review provides a brief overview of bioreactor engineering considerations. In addition, strategies for bioreactor automation, in-line product monitoring and quality assurance are discussed.
- Open Access
- 24 June 2021
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (10) , 1365-1371
Recommendations for Workforce Development in Regenerative Medicine Biomanufacturing
In its 2019 report, The Skilled Technical Workforce: Crafting America's Science and Engineering Enterprise, the National Science Board recommended a national charge to create a skilled technical workforce (STW) driven by science and engineering. The RegenMed Development Organization (ReMDO), through its RegeneratOR Workforce Development Initiative, has taken on this challenge beginning with an assessment of regenerative medicine (RM) biomanufacturing knowledge, skills, and abilities (KSAs) needed for successful employment. While STW often refers only to associate degree or other prebaccalaureate prepared technicians, the RM biomanufacturing survey included responses related to baccalaureate prepared technicians. Three levels of preparation were articulated in the research: basic employability skills, core bioscience skills, and RM biomanufacturing technical skills. The first two of these skill levels have been defined by previous research and are generally accepted as foundational—the Common Employability Skills developed by the National Network of Business and Industry Associations and the Core Skill Standards for Bioscience Technicians developed by the National Center for the Biotechnology Workforce. Fifteen skill sets addressing the specialized needs of RM and related biotechnology sectors were identified in the ReMDO survey, defining a third level of KSAs needed for entry-level employment in RM biomanufacturing. The purpose of the article is to outline the KSAs necessary for RM biomanufacturing, quantify the skills gap that currently exists between skills required by employers and those acquired by employees and available in the labor market, and make recommendations for the application of these findings.
- 24 June 2021
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (10) , 1365-1371
Open AccessRecommendations for Workforce Development in Regenerative Medicine Biomanufacturing
In its 2019 report, The Skilled Technical Workforce: Crafting America's Science and Engineering Enterprise, the National Science Board recommended a national charge to create a skilled technical workforce (STW) driven by science and engineering. The RegenMed Development Organization (ReMDO), through its RegeneratOR Workforce Development Initiative, has taken on this challenge beginning with an assessment of regenerative medicine (RM) biomanufacturing knowledge, skills, and abilities (KSAs) needed for successful employment. While STW often refers only to associate degree or other prebaccalaureate prepared technicians, the RM biomanufacturing survey included responses related to baccalaureate prepared technicians. Three levels of preparation were articulated in the research: basic employability skills, core bioscience skills, and RM biomanufacturing technical skills. The first two of these skill levels have been defined by previous research and are generally accepted as foundational—the Common Employability Skills developed by the National Network of Business and Industry Associations and the Core Skill Standards for Bioscience Technicians developed by the National Center for the Biotechnology Workforce. Fifteen skill sets addressing the specialized needs of RM and related biotechnology sectors were identified in the ReMDO survey, defining a third level of KSAs needed for entry-level employment in RM biomanufacturing. The purpose of the article is to outline the KSAs necessary for RM biomanufacturing, quantify the skills gap that currently exists between skills required by employers and those acquired by employees and available in the labor market, and make recommendations for the application of these findings.
- Open Access
- 27 August 2020
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (1) , 5-13
Regen med therapeutic opportunities for fighting COVID-19
This perspective from a Regenerative Medicine Manufacturing Society working group highlights regenerative medicine therapeutic opportunities for fighting COVID-19. This article addresses why SARS-CoV-2 is so different from other viruses and how regenerative medicine is poised to deliver new therapeutic opportunities to battle COVID-19. We describe animal models that depict the mechanism of action for COVID-19 and that may help identify new treatments. Additionally, organoid platforms that can recapitulate some of the physiological properties of human organ systems, such as the lungs and the heart, are discussed as potential platforms that may prove useful in rapidly screening new drugs and identifying at-risk patients. This article critically evaluates some of the promising regenerative medicine-based therapies for treating COVID-19 and presents some of the collective technologies and resources that the scientific community currently has available to confront this pandemic.
- 27 August 2020
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (1) , 5-13
Open AccessRegen med therapeutic opportunities for fighting COVID-19
This perspective from a Regenerative Medicine Manufacturing Society working group highlights regenerative medicine therapeutic opportunities for fighting COVID-19. This article addresses why SARS-CoV-2 is so different from other viruses and how regenerative medicine is poised to deliver new therapeutic opportunities to battle COVID-19. We describe animal models that depict the mechanism of action for COVID-19 and that may help identify new treatments. Additionally, organoid platforms that can recapitulate some of the physiological properties of human organ systems, such as the lungs and the heart, are discussed as potential platforms that may prove useful in rapidly screening new drugs and identifying at-risk patients. This article critically evaluates some of the promising regenerative medicine-based therapies for treating COVID-19 and presents some of the collective technologies and resources that the scientific community currently has available to confront this pandemic.
- Open Access
- 28 March 2020
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 9 (7) , 728-733
Improving patient outcomes with regenerative medicine: How the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence-enabled automation, education, and training
The Regenerative Medicine Manufacturing Society (RMMS) is the first and only professional society dedicated toward advancing manufacturing solutions for the field of regenerative medicine. RMMS's vision is to provide greater patient access to regenerative medicine therapies through innovative manufacturing solutions. Our mission is to identify unmet needs and gaps in regenerative medicine manufacturing and catalyze the generation of new ideas and solutions by working with private and public stakeholders. We aim to accomplish our mission through outreach and education programs and securing grants for public-private collaborations in regenerative medicine manufacturing. This perspective will cover four impact areas that the society's leadership team has identified as critical: (a) cell manufacturing and scale-up/out, respectively, for allogeneic and autologous cell therapies, (b) standards for regenerative medicine, (c) 3D bioprinting, and (d) artificial intelligence-enabled automation. In addition to covering these areas and ways in which the society intends to advance the field in a collaborative nature, we will also discuss education and training. Education and training is an area that is critical for communicating the current challenges, developing solutions to accelerate the commercialization of the latest technological advances, and growing the workforce in the rapidly expanding sector of regenerative medicine. Significance statement The Regenerative Medicine Manufacturing Society highlights focus areas to advance the field in a collaborative nature through working groups. These focus areas include cell manufacturing, standards for regenerative medicine, 3D bioprinting, and artificial intelligence-enabled automation. These working groups will help disseminate this knowledge through future publications, as well as by identifying and developing education and training programs. Education and training programs can disseminate knowledge on current challenges and new technology innovations, as well as train the next generation workforce that will assist in making therapies the next standard of care.
- 28 March 2020
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 9 (7) , 728-733
Open AccessImproving patient outcomes with regenerative medicine: How the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence-enabled automation, education, and training
The Regenerative Medicine Manufacturing Society (RMMS) is the first and only professional society dedicated toward advancing manufacturing solutions for the field of regenerative medicine. RMMS's vision is to provide greater patient access to regenerative medicine therapies through innovative manufacturing solutions. Our mission is to identify unmet needs and gaps in regenerative medicine manufacturing and catalyze the generation of new ideas and solutions by working with private and public stakeholders. We aim to accomplish our mission through outreach and education programs and securing grants for public-private collaborations in regenerative medicine manufacturing. This perspective will cover four impact areas that the society's leadership team has identified as critical: (a) cell manufacturing and scale-up/out, respectively, for allogeneic and autologous cell therapies, (b) standards for regenerative medicine, (c) 3D bioprinting, and (d) artificial intelligence-enabled automation. In addition to covering these areas and ways in which the society intends to advance the field in a collaborative nature, we will also discuss education and training. Education and training is an area that is critical for communicating the current challenges, developing solutions to accelerate the commercialization of the latest technological advances, and growing the workforce in the rapidly expanding sector of regenerative medicine. Significance statement The Regenerative Medicine Manufacturing Society highlights focus areas to advance the field in a collaborative nature through working groups. These focus areas include cell manufacturing, standards for regenerative medicine, 3D bioprinting, and artificial intelligence-enabled automation. These working groups will help disseminate this knowledge through future publications, as well as by identifying and developing education and training programs. Education and training programs can disseminate knowledge on current challenges and new technology innovations, as well as train the next generation workforce that will assist in making therapies the next standard of care.
- 27 August 2019
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 5 (4) , 162-172
Examining Resources, Initiatives, and Regulatory Pathways to Advance Regenerative Medicine Manufacturing
- 27 August 2019
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 5 (4) , 162-172
Examining Resources, Initiatives, and Regulatory Pathways to Advance Regenerative Medicine Manufacturing
- Open Access
- 15 July 2018
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 7 (8) , 564-568
An Industry-Driven Roadmap for Manufacturing in Regenerative Medicine
Regenerative medicine is poised to become a significant industry within the medical field. As such, the development of strategies and technologies for standardized and automated regenerative medicine clinical manufacturing has become a priority. An industry‐driven roadmap toward industrial scale clinical manufacturing was developed over a 3‐year period by a consortium of companies with significant investment in the field of regenerative medicine. Additionally, this same group identified critical roadblocks that stand in the way of advanced, large‐scale regenerative medicine clinical manufacturing. This perspective article details efforts to reach a consensus among industry stakeholders on the shortest pathway for providing access to regenerative medicine therapies for those in need, both within the United States and around the world. Stem Cells Translational Medicine 2018;7:564–568
- 15 July 2018
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 7 (8) , 564-568
Open AccessAn Industry-Driven Roadmap for Manufacturing in Regenerative Medicine
Regenerative medicine is poised to become a significant industry within the medical field. As such, the development of strategies and technologies for standardized and automated regenerative medicine clinical manufacturing has become a priority. An industry‐driven roadmap toward industrial scale clinical manufacturing was developed over a 3‐year period by a consortium of companies with significant investment in the field of regenerative medicine. Additionally, this same group identified critical roadblocks that stand in the way of advanced, large‐scale regenerative medicine clinical manufacturing. This perspective article details efforts to reach a consensus among industry stakeholders on the shortest pathway for providing access to regenerative medicine therapies for those in need, both within the United States and around the world. Stem Cells Translational Medicine 2018;7:564–568
- 21 April 2017
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 3 (2) , 77-82
Five Critical Areas that Combat High Costs and Prolonged Development Times for Regenerative Medicine Manufacturing
- 21 April 2017
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 3 (2) , 77-82
Five Critical Areas that Combat High Costs and Prolonged Development Times for Regenerative Medicine Manufacturing
- 14 April 2016
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 2 (2) , 118-127
Bioengineering Priorities on a Path to Ending Organ Shortage
- 14 April 2016
- Published by Springer Nature in Current Stem Cell Reports
- Vol. 2 (2) , 118-127
Bioengineering Priorities on a Path to Ending Organ Shortage
- 8 January 2016
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 11 (1) , 1
Editorial: The GAO Report: Funding, Challenges, and Solutions for Regenerative Medicine)
- 8 January 2016
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 11 (1) , 1
Editorial: The GAO Report: Funding, Challenges, and Solutions for Regenerative Medicine)
- 15 August 2015
- Published by SAGE Publications in Stem Cells and Development
- Vol. 24 (16) , 1852-1864
Induced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous System
There is great need to develop more predictive drug discovery tools to identify new therapies to treat diseases of the central nervous system (CNS). Current nonpluripotent stem cell-based models often utilize non-CNS immortalized cell lines and do not enable the development of personalized models of disease. In this review, we discuss why in vitro models are necessary for translational research and outline the unique advantages of induced pluripotent stem cell (iPSC)-based models over those of current systems. We suggest that iPSC-based models can be patient specific and isogenic lines can be differentiated into many neural cell types for detailed comparisons. iPSC-derived cells can be combined to form small organoids, or large panels of lines can be developed that enable new forms of analysis. iPSC and embryonic stem cell-derived cells can be readily engineered to develop reporters for lineage studies or mechanism of action experiments further extending the utility of iPSC-based systems. We conclude by describing novel technologies that include strategies for the development of diversity panels, novel genomic engineering tools, new three-dimensional organoid systems, and modified high-content screens that may bring toxicology into the 21st century. The strategic integration of these technologies with the advantages of iPSC-derived cell technology, we believe, will be a paradigm shift for toxicology and drug discovery efforts.
- 15 August 2015
- Published by SAGE Publications in Stem Cells and Development
- Vol. 24 (16) , 1852-1864
Induced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous System
There is great need to develop more predictive drug discovery tools to identify new therapies to treat diseases of the central nervous system (CNS). Current nonpluripotent stem cell-based models often utilize non-CNS immortalized cell lines and do not enable the development of personalized models of disease. In this review, we discuss why in vitro models are necessary for translational research and outline the unique advantages of induced pluripotent stem cell (iPSC)-based models over those of current systems. We suggest that iPSC-based models can be patient specific and isogenic lines can be differentiated into many neural cell types for detailed comparisons. iPSC-derived cells can be combined to form small organoids, or large panels of lines can be developed that enable new forms of analysis. iPSC and embryonic stem cell-derived cells can be readily engineered to develop reporters for lineage studies or mechanism of action experiments further extending the utility of iPSC-based systems. We conclude by describing novel technologies that include strategies for the development of diversity panels, novel genomic engineering tools, new three-dimensional organoid systems, and modified high-content screens that may bring toxicology into the 21st century. The strategic integration of these technologies with the advantages of iPSC-derived cell technology, we believe, will be a paradigm shift for toxicology and drug discovery efforts.